A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase 1 Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527

MC #22-42

Breast Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC), Mesothelioma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Cancer, Urothelial Cancer
Molecular Target(s)
5T4, CD137
Drug Classification(s)
Bispecific Antibodies

Mechanism of Action

ALG.APV-527 binds to both its targets, 4-1BB and 5T4. ALG.APV-527 has the potential to activate T cells and NK cells that are present in the TME in patients with various 5T4-expressing solid malignancies.


  • How much of the study agent can be given with an acceptable level of side effects
  • The effects of the study agent (good and bad)
  • How much of the study agent is absorbed into the blood and how fast it is removed
  • If research tests can be used in the future to predict who will benefit from ALG.APV527
  • How the study agent is acting on your body



Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.